Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.

We have reported previously that a canalicular multispecific organic anion transporter (cMOAT) is responsible for the biliary excretion of carboxylate forms of irinotecan, 7-ethyl-10-[4-(1-piperidino)-1 piperidino] carbonyloxy camptothecin (CPT-11), its active metabolite SN-38, and glucuronide conjugate (SN38-Glu) and the lactone form of SN38-Glu in rats. In this paper, the multiplicity of biliary excretion mechanisms for these four anionic compounds was investigated using isolated liver bile canalicular membrane vesicles (CMVs) obtained from Sprague Dawley rats. For the carboxylate form of CPT-11 and the lactone and carboxylate forms of SN38-Glu, ATP-dependent uptake consisted of both high- and low-affinity components in CMVs. Mutual inhibition studies with S-(2,4-dinitrophenyl)glutathione, a representative substrate for cMOAT, and the uptake study using CMVs from Eisai hyperbilirubinemic rats revealed that cMOAT is responsible for the biliary excretion of the low-affinity component of the carboxylate form of CPT-11 and the high-affinity component of both the lactone and carboxylate forms of SN38-Glu, whereas the high-affinity component for CPT-11 and the low-affinity component for SN38-Glu, which are expressed in Eisai hyperbilirubinemic rats, are governed by a transporter different from cMOAT. The carboxylate form of SN-38 was found to be transported by cMOAT alone. We conclude that multiple transporters, including cMOAT, are responsible for the biliary excretion of CPT-11 and its metabolites (anionic forms), and the contribution of each transporter differs greatly, depending on the substrates.

[1]  M. Ratain,et al.  Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. , 1996, Cancer research.

[2]  R. Evers,et al.  Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. , 1996, The Journal of clinical investigation.

[3]  D. Keppler,et al.  ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. , 1996, The Biochemical journal.

[4]  P. Bosma,et al.  Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene , 1996, Science.

[5]  Y. Sugiyama,et al.  Expression of a putative ATP-binding cassette region, homologous to that in multidrug resistance-associated protein (MRP), is hereditarily defective in Eisai hyperbilirubinemic rats (EHBR) , 1996 .

[6]  D. Keppler,et al.  Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport- deficient mutant hepatocytes , 1995, The Journal of cell biology.

[7]  Y. Sugiyama,et al.  Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats. , 1995, The Journal of pharmacology and experimental therapeutics.

[8]  D. Keppler,et al.  The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. , 1994, The Journal of biological chemistry.

[9]  D. Keppler,et al.  ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. , 1994, Cancer research.

[10]  Y. Pommier,et al.  Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. , 1994, Journal of the National Cancer Institute.

[11]  D. Keppler,et al.  ATP‐dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P‐glycoprotein , 1994, FEBS letters.

[12]  Y. Sugiyama,et al.  Kinetic analysis of hepatobiliary transport of organic anions in Eisai hyperbilirubinemic mutant rats. , 1993, The Journal of pharmacology and experimental therapeutics.

[13]  M. Iigo,et al.  Relationship between Development of Diarrhea and the Concentration of SN‐38, an Active Metabolite of CPT‐11, in the Intestine and the Blood Plasma of Athymic Mice Following Intraperitoneal Administration of CPT‐11 , 1993, Japanese journal of cancer research : Gann.

[14]  E K Rowinsky,et al.  The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.

[15]  C. Higgins,et al.  ABC transporters: from microorganisms to man. , 1992, Annual review of cell biology.

[16]  V. Stella,et al.  A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. , 1992, Journal of pharmaceutical sciences.

[17]  M. Fukuoka,et al.  Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. , 1991, Journal of the National Cancer Institute.

[18]  R. Ohno,et al.  An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Hayashi,et al.  Mechanism of glutathione S-conjugate transport in canalicular and basolateral rat liver plasma membranes. , 1990, The Journal of biological chemistry.

[20]  K. Kohn,et al.  Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.

[21]  Y. Suzuki,et al.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[23]  Y. Sugiyama,et al.  Multiple transport systems for organic anions across the bile canalicular membrane. , 1994, The Journal of pharmacology and experimental therapeutics.

[24]  H. Hakusui,et al.  Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. , 1991, Xenobiotica; the fate of foreign compounds in biological systems.